ライフサイエンスコーパス: vancomycin-resistant enterococci

1 s) and can acquire resistance to vancomycin (vancomycin-resistant enterococci).

2 ese patients may help decrease the spread of vancomycin-resistant enterococci.

3 oft-tissue infections, and infections due to vancomycin-resistant enterococci.

4 und in a subset of 875 recent US isolates of vancomycin-resistant enterococci.

5 - and vancomycin-resistant Staphylococci and vancomycin-resistant Enterococci.

6 There were no vancomycin-resistant enterococci.

7 tions such as relapses and infections due to vancomycin-resistant enterococci.

8 A and B two-component regulatory switches in vancomycin-resistant enterococci.

9 omologous D-Ala:D-lactate ligase produced by vancomycin-resistant enterococci.

10 s used for molecular epidemiologic typing of vancomycin-resistant enterococci.

11 3%) environmental cultures were positive for vancomycin-resistant enterococci.

12 icobacter pylori, Neisseria gonorrhoeae, and vancomycin-resistant enterococci.

13 uently used as a drug of last resort against vancomycin-resistant enterococci.

14 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci.

15 e-positive results due to contamination with vancomycin-resistant enterococci.

16 system regulates the resistance phenotype of vancomycin-resistant enterococci.

17 aureus, vancomycin-resistant S. aureus, and vancomycin-resistant enterococci.

18 mug/mL), including enhanced potency against vancomycin-resistant enterococci.

19 ed off-label to treat patients infected with vancomycin-resistant enterococci.

20 stance to daptomycin during the treatment of vancomycin-resistant enterococci.

21 reus, vancomycin-intermediate S. aureus, and vancomycin-resistant Enterococci.

22 ureus, vancomycin-intermediate S. aureus and vancomycin-resistant enterococci.

23 with linezolid for bloodstream infections by vancomycin-resistant enterococci.

24 cocci, macrolide-resistant streptococci, and vancomycin-resistant enterococci.

25 etection of gastrointestinal colonization by vancomycin-resistant enterococci.

26 i and to assess molecular characteristics of vancomycin-resistant enterococci, 157 clinical blood iso

27 trol policies to prevent the transmission of vancomycin-resistant enterococci (22 of 25 [88 percent]

28 f the long-term care facilities screened for vancomycin-resistant enterococci (26 of 28 in 1998 [93 p

29 coccus aureus (43% [31-54; I(2) 95.9%]), and vancomycin-resistant enterococci (41% [26-56; I(2) 96.2%

30 The VanA ligase of vancomycin-resistant enterococci, a D-Ala-D-lactate deps

31 phalosporin-resistant enterobacteriaceae and vancomycin-resistant enterococci (acquired antibiotic re

32 Vancomycin-resistant enterococci and Klebsiella pneumoni

33 ive against Gram-positive bacteria including vancomycin-resistant enterococci and methicillin-resista

34 th of antibiotic resistant superbugs such as vancomycin-resistant Enterococci and Staphylococci has b

35 resistant to drugs of last resort, including vancomycin-resistant enterococci and staphylococci, has

36 ancomycins (AAVs), with high potency against vancomycin-resistant enterococci and staphylococci.

37 h hydrophobic side chains are active against vancomycin-resistant enterococci and vancomycin-resistan

38 s aeruginosa, and vancomycin-susceptible and vancomycin-resistant enterococci and with 193 perianal s

39 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci, and (3) optimization o

40 -lactamase-producing Gram-negative bacteria, vancomycin-resistant enterococci, and Clostridium diffic

41 study of gastrointestinal colonization with vancomycin-resistant enterococci, and compared infection

42 including meticillin-resistant Staph aureus, vancomycin-resistant enterococci, and penicillin-resista

43 us aureus, coagulase-negative staphylococci, vancomycin-resistant enterococci, and resistance to thir

44 ococci; the number of days to acquisition of vancomycin-resistant enterococci; and other measurements

45 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci), antifungal socks (whi

46 Vancomycin-resistant enterococci are a major cause of no

47 Vancomycin-resistant enterococci are an important cause

48 d, 900-bed, urban teaching hospital in which vancomycin-resistant enterococci are endemic.

49 l intensive care unit of a hospital in which vancomycin-resistant enterococci are endemic.

50 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci as well as hemolytic ac

51 study of 51 patients who were colonized with vancomycin-resistant enterococci, as evidenced by the pr

52 The overall prevalence of vancomycin-resistant enterococci at 30 facilities that p

53 control practices and screening policies for vancomycin-resistant enterococci at the acute care and l

54 A rapid protocol for subtyping vancomycin-resistant enterococci by pulsed-field gel ele

55 meticillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, C difficile, and multi

56 methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, carbapenem-resistant E

57 nd more methicillin-resistant staphylococci, vancomycin-resistant enterococci, ceftriaxone-resistant

58 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci clinical isolates and i

59 ities that had had at least one patient with vancomycin-resistant enterococci declined from 15 in 199

60 a bacteriocin that is highly potent against vancomycin-resistant enterococci, depends on binding to

61 t methicillin-resistant S. aureus (MRSA) and vancomycin-resistant enterococci, evades substantial res

62 e of D-serine for peptidoglycan synthesis in vancomycin-resistant enterococci expressing the VanC phe

63 HAIs included clinical cultures positive for vancomycin-resistant enterococci, extended-spectrum beta

64 tibacterial assays employing a unique set of vancomycin-resistant Enterococci faecalis and Enterococc

65 ncomycin-sensitive Staphylococcus aureus and vancomycin-resistant Enterococci faecalis as well as the

66 her derivative of vancomycin aglycon against vancomycin-resistant Enterococci faecalis previously rep

67 Two isolates among vancomycin-resistant enterococci from the greater Housto

68 inst methicillin-resistant staphylococci and vancomycin-resistant enterococci has been purified, and

69 Colonization and infection with vancomycin-resistant enterococci have been associated wi

70 the US Food and Drug Administration to treat vancomycin-resistant enterococci; however, resistance to

71 hazard ratio [HR], 0.20; 95% CI, 0.04-1.09), vancomycin-resistant enterococci (HR, 0.84; 95% CI, 0.46

72 ceptional growth inhibitory activity against vancomycin-resistant Enterococci (IC50 40 nM), >270-fold

73 screening and infection-control policies for vancomycin-resistant enterococci in 1998 and 1999.

74 es only in preventing rectal colonization by vancomycin-resistant enterococci in a medical intensive

75 We examined the density of vancomycin-resistant enterococci in stool during and aft

76 When the density of vancomycin-resistant enterococci in stool was at least 4

77 For patients with vancomycin-resistant enterococci in stool, treatment wit

78 The advent of vancomycin-resistant enterococci in the 1990s and the th

79 can reduce or eliminate the transmission of vancomycin-resistant enterococci in the health care faci

80 21 (23.9%) in the glove-only group acquired vancomycin-resistant enterococci in the medical intensiv

81 on was sought in assessing the prevalence of vancomycin-resistant enterococci in the region's facilit

82 oratories conducting active surveillance for vancomycin-resistant enterococci in three San Francisco

83 evention received a report of an outbreak of vancomycin-resistant enterococci in which 31 of 84 (36.9

84 Risk factors for acquisition of vancomycin-resistant enterococci induced length of stay

85 oral vancomycin did not increase the risk of vancomycin-resistant Enterococci infection at 3 or 6 mon

86 analyses, we detected an overall increase in vancomycin-resistant enterococci infections post-ASP (1.

87 eremia, Clostridium difficile infection, and vancomycin-resistant enterococci infections prevented in

88 ible P aeruginosa (IRR 2.06 [1.91-2.21]) and vancomycin-resistant enterococci (IRR 3.06 [2.89-3.24]).

89 ains or hospitals in which the prevalence of vancomycin-resistant enterococci is low.

90 the major challenges when using DAP against vancomycin-resistant enterococci is the emergence of res

91 as multidrug-resistant Enterobacterales and vancomycin-resistant enterococci, is associated with inc

92 s and Enterococcus gallinarum (intrinsically vancomycin-resistant enterococci [IVRE]) from Enterococc

93 All 465 (100%) vancomycin-resistant enterococci (MIC > or = 32 microgra

94 p and 13 (14.8%) in the glove-only group had vancomycin-resistant enterococci on admission to the med

95 ersus without any apparent MDROs (P = .009), vancomycin-resistant enterococci (P = .008), multidrug-r

96 If the total number of vancomycin-resistant enterococci patients in the ICU wer

97 b-lacZ fusions report on expression from the vancomycin-resistant enterococci promoters of the type A

98 resistance upon serial exposure against two vancomycin-resistant enterococci strains where its activ

99 vanHAX are orthologous to genes found in vancomycin-resistant enterococci that encode enzymes pre

100 The number of patients becoming colonized by vancomycin-resistant enterococci; the number of days to

101 mice that have intestinal colonization with vancomycin-resistant enterococci, these agents promote h

102 cago, IL and tested for the following MDROs: vancomycin-resistant enterococci; third-generation cepha

103 ata from an interrupted time-series study of vancomycin-resistant enterococci transmission in a hemat

104 ) domains of two VanS proteins, derived from vancomycin-resistant enterococci types A and C.

105 ising improvement of its bioactivity against vancomycin-resistant enterococci (Van A and Van B phenot

106 In pathogenic vancomycin-resistant enterococci, vanX is part of a five

107 Data regarding the effectiveness of vancomycin resistant Enterococci (VRE) active prophylaxi

108 ent-specific risk factors for acquisition of vancomycin-resistant enterococci (VRE) among hospitalize

109 ces healthcare-associated infection rates of vancomycin-resistant enterococci (VRE) and Clostridioide

110 The transmission dynamics of vancomycin-resistant enterococci (VRE) and factors contr

111 We analyzed surveillance cultures for vancomycin-resistant enterococci (VRE) and methicillin-r

112 gy laboratory to determine the prevalence of vancomycin-resistant enterococci (VRE) and multidrug-res

113 to selective enrichment broth for detecting vancomycin-resistant enterococci (VRE) and multidrug-res

114 Surveillance cultures for vancomycin-resistant enterococci (VRE) and subsequent ch

115 se of potential postpartum infections due to vancomycin-resistant enterococci (VRE) and the possible

116 ctively analyzed risk factors and outcome of vancomycin-resistant enterococci (VRE) and vancomycin-se

117 erococcus faecalis bacteremia caused by both vancomycin-resistant enterococci (VRE) and vancomycin-su

118 Vancomycin-resistant enterococci (VRE) are a major cause

119 Vancomycin-resistant enterococci (VRE) are a major cause

120 Vancomycin-resistant enterococci (VRE) are an important

121 Vancomycin-resistant enterococci (VRE) are common hospit

122 Vancomycin-resistant enterococci (VRE) are high-priority

123 Vancomycin-resistant enterococci (VRE) are increasingly

124 Vancomycin-resistant enterococci (VRE) are increasingly

125 Vancomycin-resistant enterococci (VRE) are nosocomial pa

126 Vancomycin-resistant enterococci (VRE) are the second le

127 Surveillance cultures for vancomycin-resistant enterococci (VRE) are time-consumin

128 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) are under increas

129 Treatment options for vancomycin-resistant enterococci (VRE) bloodstream infec

130 y-associated CDI (CO-HCFA-CDI), incidence of vancomycin-resistant Enterococci (VRE) colonization afte

131 y-associated CDI (CO-HCFA-CDI), incidence of vancomycin-resistant Enterococci (VRE) colonization afte

132 ta in the colon inhibit the establishment of vancomycin-resistant enterococci (VRE) colonization by d

133 concentrations, did not promote significant vancomycin-resistant enterococci (VRE) colonization.

134 d by the National Healthcare Safety Network, vancomycin-resistant enterococci (VRE) continue to affli

135 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) due to the scope

136 Vancomycin-resistant enterococci (VRE) escape the bacter

137 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) for extended peri

138 r (BBL, Sparks, Md.) for direct detection of vancomycin-resistant enterococci (VRE) from 894 perianal

139 Xpert vanA assay for routine surveillance of vancomycin-resistant enterococci (VRE) from rectal swabs

140 ug/ml vancomycin (BEAV) for the isolation of vancomycin-resistant enterococci (VRE) from stool specim

141 The treatment of infections caused by vancomycin-resistant enterococci (VRE) has become an imp

142 incidence of colonization and infection with vancomycin-resistant enterococci (VRE) has increased dra

143 Vancomycin-resistant enterococci (VRE) have emerged as n

144 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) have now arisen a

145 rs were compared for their ability to detect vancomycin-resistant enterococci (VRE) in 750 stool spec

146 ve E. faecium, which implies that control of vancomycin-resistant enterococci (VRE) in hospitals also

147 -resistant Staphylococcus aureus (EMRSA) and vancomycin-resistant enterococci (VRE) in hospitals in E

148 Active screening for vancomycin-resistant enterococci (VRE) in rectal and sto

149 As infection with vancomycin-resistant enterococci (VRE) increases in hosp

150 Gram-positive bacteria and the prevalence of vancomycin-resistant Enterococci (VRE) infections are hi

151 ), Clostridium difficile infection (CDI) and vancomycin-resistant enterococci (VRE) infections preven

152 tly disrupts the gut microbiome and promotes vancomycin-resistant enterococci (VRE) intestinal coloni

153 he identification of patients colonized with vancomycin-resistant enterococci (VRE) is central to the

154 Vancomycin resistance in vancomycin-resistant enterococci (VRE) is due to an alte

155 that a method of performing surveillance for vancomycin-resistant enterococci (VRE) is to screen spec

156 e gastrointestinal tracts are colonized with vancomycin-resistant enterococci (VRE) may serve as a re

157 esistant Staphylococcus aureus (MRSA) and/or vancomycin-resistant enterococci (VRE) on at least 1 occ

158 Vancomycin-resistant enterococci (VRE) recently have eme

159 Vancomycin-resistant enterococci (VRE) represent a growi

160 biquitous on plasmids isolated from clinical vancomycin-resistant enterococci (VRE) strains.

161 ents using rectal swabs from an existing ICU vancomycin-resistant enterococci (VRE) surveillance prog

162 nts, using rectal swabs from an existing ICU vancomycin-resistant Enterococci (VRE) surveillance prog

163 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) that are known to

164 Vancomycin resistance is conferred upon vancomycin-resistant enterococci (VRE) through the repla

165 trains to the establishment of endemicity of vancomycin-resistant enterococci (VRE) were determined.

166 the Massachusetts General Hospital from whom vancomycin-resistant enterococci (VRE) were isolated fro

167 Among our patient population, more vancomycin-resistant enterococci (VRE) were recovered wi

168 typic variation and stability of isolates of vancomycin-resistant enterococci (VRE) were studied to d

169 tant Staphylococcus aureus (MRSA) as well as vancomycin-resistant enterococci (VRE) with minimum inhi

170 -pyridone backbone, which are active against vancomycin-resistant enterococci (VRE), a serious threat

171 tiresistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), among patients i

172 llin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and ceftazidime-

173 set (HO) gram-negative rod (GNR) bacteremia, vancomycin-resistant Enterococci (VRE), and Clostridioid

174 , as well as glycopeptides effective against vancomycin-resistant enterococci (VRE), and fluoroquinol

175 vancomycin (BEAV) agar (84.8%) for detecting vancomycin-resistant enterococci (VRE), and the results

176 With increasing prevalence of vancomycin-resistant enterococci (VRE), appropriate anti

177 llin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), carbapenem-resis

178 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), has reached a cr

179 ibiotic-resistant bacterial species, such as vancomycin-resistant enterococci (VRE), necessitates the

180 Vancomycin-resistant enterococci (VRE), particularly Ent

181 anA/vanB DNA hybridization assay to identify vancomycin-resistant enterococci (VRE), was evaluated fo

182 ulty in detecting intermediate and low-level vancomycin-resistant enterococci (VRE).

183 omycin per ml and evaluated for isolation of vancomycin-resistant enterococci (VRE).

184 epted method for detecting colonization with vancomycin-resistant enterococci (VRE).

185 in antimicrobial potency (200-fold) against vancomycin-resistant Enterococci (VRE).

186 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE).

187 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

188 ence of vancomycin-resistant strains such as vancomycin-resistant Enterococci (VRE).

189 agar plates as negative or "nonnegative" for vancomycin-resistant enterococci (VRE).

190 ncomycin may increase selection pressure for vancomycin-resistant Enterococci (VRE).

191 to develop an antimicrobial peptide against vancomycin-resistant enterococci (VRE).

192 ater than 1000-fold was demonstrated against vancomycin-resistant Enterococci (VRE).

193 nsive care unit for rectal colonization with vancomycin-resistant enterococci (VRE).

194 han vancomycin and has activity against many vancomycin-resistant enterococci (VRE).

195 t contribute to the transmission dynamics of vancomycin-resistant enterococci (VRE).

196 in-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant enterococci (VRE).

197 treatment of patients with stool carriage of vancomycin-resistant enterococci (VRE).

198 In 1996, the dominant (43%) strain of vancomycin-resistant enterococci (VRE; type A) at Massac

199 rococcal bloodstream infection (BSI; 22 with vancomycin-resistant enterococci [VRE] and 61 with vanco

200 n-resistant Staphylococcus aureus [MRSA] and vancomycin-resistant enterococci [VRE]) or rapid screeni

201 (95 percent), high-density colonization with vancomycin-resistant enterococci was maintained (mean [+

202 All 36 vancomycin-resistant enterococci were detected by the Ph

203 Nineteen types of vancomycin-resistant enterococci were documented by puls

204 In late 1996, vancomycin-resistant enterococci were first detected in

205 hicillin-resistant Staphylococcus aureus, or vancomycin-resistant enterococci were included.

206 ties, the risk factors for colonization with vancomycin-resistant enterococci were prior hospitalizat

207 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci, without affecting the

208 mutant subsequently resulted in clearance of vancomycin-resistant enterococci, without plasmid transf